|
||
Femodene Uses |
||
Menopausal hormone replacement therapy
Adult: In menopausal women: 10-20 mcg daily in conjunction with a progestogen in women with uterus.
Female hypogonadism
Adult: 10-50 mcg daily in a cyclical regimen.
Palliative treatment of breast carcinoma
Adult: In postmenopausal women: 0.1-1 mg tid.
Palliative treatment of prostatic carcinoma
Adult: 0.15-3 mg daily.
As part of combined oral contraceptive
Adult: As the oestrogenic component of combined oral contraceptive: 20-40 mcg/day.
Generally refers to the 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Femodene-17-beta is the most potent form of mammalian estrogenic steroids. In humans, it is produced primarily by the cyclic ovaries and the placenta. It is also produced by the adipose tissue of men and postmenopausal women. The 17-alpha-isomer of estradiol binds weakly to estrogen receptors (receptors, estrogen) and exhibits little estrogenic activity in estrogen-responsive tissues. Various isomers can be synthesized.
Menopausal hormone replacement therapy
Adult: In menopausal women: 10-20 mcg daily in conjunction with a progestogen in women with uterus.
Female hypogonadism
Adult: 10-50 mcg daily in a cyclical regimen.
Palliative treatment of breast carcinoma
Adult: In postmenopausal women: 0.1-1 mg tid.
Palliative treatment of prostatic carcinoma
Adult: 0.15-3 mg daily.
As part of combined oral contraceptive
Adult: As the oestrogenic component of combined oral contraceptive: 20-40 mcg/day.
Concurrent use with hepatic enzyme inducers e.g. barbiturates, primidone, phenobarbitone, phenytoin, phenylbutazone, rifampicin, carbamazepine and griseofulvin may affect contraceptive efficacy. Short courses of broad-spectrum antibiotics may also reduce the efficacy of the oral contraceptive. Concurrent use with HIV protease and non-nucleoside reverse transcriptase inhibitors may affect hepatic metabolism of Femodene and/or Femodene. May increase plasma concentrations of ciclosporin and decrease the serum levels of lamotrigine. Concurrent use with felbamate may increase the clearance of Femodene. Femodene may increase serum levels of buprenorphine. Co-trimoxazole, miconazole and etoricoxib may increase serum levels of Femodene. Aprepitant, modafinil and bosentan may reduce the serum levels of Femodene. Metabolism of omeprazole may be inhibited by Femodene. GI absorption of Femodene may be increased by concurrent admin of paracetamol.
Food Interaction
Concurrent treatment with St John’s wort may reduce efficacy of the oral contraceptive.
Menstrual irregularities; headache, dizziness; breast discomfort; gynaecomastia; depression; disturbance of appetite; wt changes; fluid retention; oedema; changes in libido; hair loss or hirsutism; GI disturbances (nausea and vomiting); genitourinary changes; haematologic disorders; endocrine and metabolic disorders; cholestatic jaundice; local skin reactions; chorea; contact lens intolerance; steeping of corneal curvature; pulmonary thromboembolism; carbohydrate and/or glucose intolerance; depression; chloasma; BP increase, liver impairment; reduced menstrual loss, ’spotting’ in early cycles, absence of withdrawal bleeding; rarely photosensitivity; increased risk in breast cancer; elevation of plasma bound iodine, cortisol and thyroid binding, erythrocyte sedimentation may be accelerated; increases in plasma copper, iron and alkaline phosphatase; may affect serum triglyceride and lipoprotein levels; retinal vascular thrombosis.
Potentially Fatal: Hepatic tumours; increased risk of thromboembolism.
Estrogens should not be used in individuals with any of the following conditions:
1. Undiagnosed abnormal genital bleeding.
2. Known, suspected, or history of cancer of the breast.
3. Known or suspected estrogen-dependent neoplasia
4. Active deep vein thrombosis, pulmonary embolism, or history of these conditions.
5. Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction).
6. Liver dysfunction or disease.
7. EstroGel therapy should not be used in patients with known hypersensitivity to its ingredients.
8. Known or suspected pregnancy. There is no indication for EstroGel in pregnancy. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy.
Ethinylestradiol in Belgium, Georgia, Luxembourg, South Africa, United Kingdom.
Gestodene in Belgium, Luxembourg, South Africa, United Kingdom.
Unit description / dosage (Manufacturer) | Price, USD |
Tablet, Sugar-Coated; Oral; Ethinyl Estradiol 0.03 mg; Gestodene 0.075 mg | |
List of Femodene substitutes (brand and generic names): | |
Evecontra (India) | |
EVECONTRA tab 28's (Amra (Womencare)) | $ 3.37 |
Gestadene (Switzerland) | |
Gestodene (Australia, Austria, Belgium, Brazil, Chile, China, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, Mexico, Netherlands, Oman, Poland, Portugal, Slovenia, Spain, Switzerland, Venezuela) | |
Gestodène | |
Ginette 35 | |
Ginette 35 Ethinyl Estradiol 0.035mg, Cyproterone Acetate 2mg, 21yellow coloured active filmcoated tablets and 7 whitecoloured placebo film KIT / 28 | $ 2.36 |
Ginette 35 Ethinyl Estradiol 0.035mg, Cyproterone Acetate 2mg, 21yellow coloured active filmcoated tablets and 7 whitecoloured placebo film KIT / 21 | $ 2.52 |
Ginette 35 Tablet (Cipla Ltd) | $ 0.16 |
Gynofen-35 (Greece) | |
Lenest 20 ED (Australia) | |
LOCIPIL (India) | |
21's (Corona (Aarush)) | $ 1.14 |
Locipil Ethinylestradiol 0.02 mg, Desogestrel 0.15 mg. TAB / 21 (Corona (Aarush)) | $ 1.42 |
LOCIPIL 0.03 MG/0.15 MG TABLET 1 strip / 21 tablets each (Corona (Aarush)) | $ 1.81 |
LOCIPIL tab 21's (Corona (Aarush)) | $ 1.69 |
Locipil Ethinylestradiol 0.02 mg, Desogestrel 0.15 mg. TAB / 21 (Corona (Aarush)) | $ 1.42 |
Locipil 0.03 mg/0.15 mg Tablet (Corona (Aarush)) | $ 0.09 |
Lusia F | |
Lusia F Norgestrel 0.3mg, EthinylEstradiol 0.03mg, Fe Fumerate75mg TAB / 28 | |
Lynoral (India, Indonesia, Netherlands, Sri Lanka) | |
Tablet; Oral; Ethinyl Estradiol 0.01 mg (Organon) | |
Tablet; Oral; Ethinyl Estradiol 0.05 mg (Organon) | |
LYNORAL Capsule/ Tablet / 0.05mg / 10 units (Organon) | $ 0.59 |
LYNORAL Capsule/ Tablet / 1mg / 10 units (Organon) | $ 0.31 |
LYNORAL Capsule/ Tablet / 0.01mg / 10 units (Organon) | $ 0.40 |
Lynoral 50 mcg x 100's (Organon) | $ 16.58 |
Lynoral 0.01mg TAB / 10 (Organon) | $ 0.41 |
Lynoral 0.05mg TAB / 10 (Organon) | $ 0.22 |
Lynoral 1mg TAB / 10 (Organon) | $ 0.31 |
0.01 mg x 10's (Organon) | $ 0.41 |
0.05 mg x 10's (Organon) | $ 0.22 |
1 mg x 10's (Organon) | $ 0.31 |
LYNORAL 0.01 MG TABLET 1 strip / 10 tablets each (Organon) | $ 0.27 |
LYNORAL 0.05 MG TABLET 1 strip / 10 tablets each (Organon) | $ 0.46 |
LYNORAL 1 MG TABLET 1 strip / 10 tablets each (Organon) | $ 0.27 |
LYNORAL tab 0.01 mg x 10's (Organon) | $ 0.58 |
LYNORAL tab 0.05 mg x 10's (Organon) | $ 0.88 |
LYNORAL tab 1 mg x 10's (Organon) | $ 0.31 |
Lynoral 0.01mg Tablet (Organon) | $ 0.03 |
Lynoral 1mg Tablet (Organon) | $ 0.03 |
Manodiol (Thailand) | |
Manodiol 50 x 28's (March Pharma) | |
Manodiol tab 50 x 28's (March Pharma) | |
Mixogen TAB | |
Mixogen TAB Ethinyl Estradiol 0.0044mg, Methyltosterone 3.6mg TAB / 10 | $ 0.25 |
Neogynon (Colombia, Ethiopia, Mexico) | |
Tablet, Sugar-Coated; Oral; Ethinyl Estradiol 0.05 mg; Levonorgestrel 0.25 mg (Schering) | |
Nortrel 1/35 21 (United States) | |
Orgalutin | |
Orgalutin 2.5+0.05 Tablet (Infar (India) Ltd) | $ 0.03 |
See 102 substitutes for Femodene |
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|